Food Chemistry, Journal Year: 2020, Volume and Issue: 346, P. 128898 - 128898
Published: Dec. 25, 2020
Language: Английский
The Lancet Neurology, Journal Year: 2022, Volume and Issue: 22(2), P. 147 - 158
Published: Oct. 28, 2022
Language: Английский
Citations
80
Addiction, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 13, 2025
Abstract Background and Aims Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as potential therapeutic target due its pharmacological properties mode action in the endocannabinoid system. Recent systematic reviews (SR) on CBD SUDs have shown inconsistent results. The objective this umbrella review was determine whether alone or combination with Δ‐9‐tetrahydrocannabinol (THC) effective for managing treating SUDs. Methods Following registered protocol, we searched PubMed, Web Science Epistemonikos databases SRs, without meta‐analysis, randomized controlled trials focusing interventions dispensing CBD, THC, treat SUDs, published from 1 January 2000 15 October 2024. Screening, data extraction quality assessment AMSTAR 2 tool were performed by two researchers parallel duplicated. Results 22 SRs included, 5 which meta‐analysis. We found mixed evidence regarding efficacy manage Findings interpreted light SRs. Nabiximols, contains demonstrated positive effects cannabis withdrawal craving symptoms. Evidence supporting limited inconclusive abstinence, reduction cessation cannabis, tobacco, alcohol, opiates other psychoactive substances. Conclusion monotherapy does not appear be efficacious substance disorders. primarily exhibits when combined (THC). Existing regard outcomes related
Language: Английский
Citations
2
AIMS neuroscience, Journal Year: 2021, Volume and Issue: 8(3), P. 414 - 434
Published: Jan. 1, 2021
Existing reviews exploring cannabis effectiveness have numerous limitations including narrow search strategies. We systematically explored effects on PTSD symptoms, quality of life (QOL), and return to work (RTW). also investigated harm outcomes such as adverse dropouts due effects, inefficacy, all-cause dropout rates.Our in MEDLINE, EMBASE, PsycInfo, CINAHL, Web Science, CENTRAL, PubMed databases, yielded 1 eligible RCT 10 observational studies (n = 4672). Risk bias (RoB) was assessed with the Cochrane risk tool ROBINS-I.Evidence from included mainly based non-randomized no comparators. Results unpooled, high RoB showed that associated a reduction overall symptoms improved QOL. Dry mouth, headaches, psychoactive agitation euphoria were commonly reported effects. In most studies, well tolerated, but small proportions patients experienced worsening symptoms.Evidence current study primarily stems low studies. Further RCTs investigating treatment should be conducted larger sample sizes explore broader range patient-important outcomes.
Language: Английский
Citations
48
Psychiatry Research, Journal Year: 2021, Volume and Issue: 308, P. 114347 - 114347
Published: Dec. 20, 2021
Language: Английский
Citations
48
Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(12), P. 2598 - 2598
Published: Nov. 25, 2022
(1) Background: With the massive demand for use and commercialization of medicinal cannabidiol (CBD) products, new randomized clinical trials (RCTs) are being published worldwide, with a constant need safety efficacy evaluation. (2) Methods: We performed an update on systematic review in 2020 that focused analyzing serious adverse effects (SAEs) CBD RCTs its possible association drug interactions. also updated report most prevalent (AEs). systematically searched EMBASE, MEDLINE/PubMed, Web Science without language restriction reported after repeated oral administration at least one week healthy volunteers or samples from January 2019 to May 2022. The included studies were assessed methodological quality by Quality Assessment Controlled Intervention Studies tool. present is registered PROSPERO, number CRD42022334399. (3) Results: Twelve involving 745 subjects analyzed (range 1.1-56.8 y). A total 454 participants used trials. common AEs mild moderate gastrointestinal symptoms (59.5%), somnolence (16.7%), loss appetite (16.5%), hypertransaminasemia (ALT/AST) (12.8%). Serious include mainly serum levels elevations greater than three times upper limit normal (6.4%), seizures (1.3%), rash (1.1%). All SAEs observed as add-on therapy anticonvulsant medications, including clobazam valproate. (4) Conclusion: Recent suggest has good tolerability profile, confirming previous data. However, it can potentially interact other drugs should be monitored, especially beginning treatment.
Language: Английский
Citations
38
International Journal of Drug Policy, Journal Year: 2021, Volume and Issue: 97, P. 103278 - 103278
Published: July 23, 2021
Language: Английский
Citations
33
European Child & Adolescent Psychiatry, Journal Year: 2023, Volume and Issue: 33(2), P. 505 - 526
Published: March 3, 2023
A better understanding of the endocannabinoid system and a relaxation in regulatory control cannabis globally has increased interest medicinal use cannabinoid-based products (CBP). We provide systematic review rationale current clinical trial evidence for CBP treatment neuropsychiatric neurodevelopmental disorders children adolescents. search MEDLINE, Embase, PsycINFO, Cochrane Central Register Trials was performed to identify articles published after 1980 about medical purposes individuals aged 18 years or younger with selected conditions. Risk bias quality assessed each article. Of 4466 screened, were eligible inclusion, addressing eight conditions (anxiety (n = 1); autism spectrum disorder 5); foetal alcohol fragile X syndrome 2); intellectual disability mood post-traumatic stress 3); Tourette 3)). Only one randomised controlled (RCT) identified. The remaining seventeen included open-label trial, three uncontrolled before-and-after trials, two case series 11 reports, thus risk high. Despite growing community scientific interest, our identified limited generally poor-quality efficacy Large rigorous RCTs are required inform care. In meantime, clinicians must balance patient expectations available.
Language: Английский
Citations
14
Brain Sciences, Journal Year: 2024, Volume and Issue: 14(6), P. 592 - 592
Published: June 10, 2024
The endocannabinoid system has been linked to various physiological and pathological processes, because it plays a neuromodulator role in the central nervous system. In this sense, cannabinoids have used off-label for neurodevelopmental disorders, such as autism spectrum disorder (ASD) attention-deficit/hyperactivity (ADHA), well Alzheimer's disease (AD), more prevalent neurodegenerative disease. Thus, study aims, through comprehensive literature review, arrive at better understanding of impact therapeutic treatment patients with ASD, ADHD, (AD). Overall, cannabis products rich CBD displayed higher potential ASD children, while THC tested AD therapy. For clinical studies are incipient inconclusive, but promising. general, main limitations lack standardization cannabis-based consumed by participants, scientific rigor, small number participants.
Language: Английский
Citations
6
Nordic Studies on Alcohol and Drugs, Journal Year: 2021, Volume and Issue: 38(3), P. 270 - 292
Published: Feb. 25, 2021
In Denmark the boundaries between cannabis as an illicit drug and licit medicine have shifted rapidly in recent years, affecting also policy. However, vast majority of Danes, who use (CaM) continue to rely on unregulated market for supply. This study explores patterns motives CaM Denmark.An anonymous online survey was made available a convenience sample users from July 14, 2018 November 1, 2018. Participants were recruited through patient organisations, social public media, illegal open market.Of final (n = 3,021), women (62.6%) mean age 49 years. Most had no prescription (90.9%), or limited previous experience with recreational (63.9%), used two years less (65.0%). The most common form intake oil (56.8%) followed by smoke (24.0%). CBD (65.0%) more than hash, pot skunk (36.2%). frequent conditions treated chronic pain (32.0%), sleep disturbances (27.5%), stress (23.7%), osteoarthritis (22.7%), anxiety (19.6%), depression (19.6%). Overall, experienced be effective managing somatic mental health reported relatively few side-effects. only likely women, older, initiated recently.A new user group has emerged that, part, illegally sourced treat broad range conditions, often effect low level prevalent low-potency indicates interest effects beyond high normally associated use. More clinical research into side-effects is needed draw medical utility cannabis.
Language: Английский
Citations
31
Biomolecules, Journal Year: 2022, Volume and Issue: 12(10), P. 1462 - 1462
Published: Oct. 12, 2022
Cannabidiol (CBD) is a non-intoxicating cannabinoid compound with diverse molecular targets and potential therapeutic effects, including effects relevant to the treatment of psychiatric disorders. In this scoping review, we sought determine extent which sex gender have been considered as moderators neuropsychiatric pharmacokinetics CBD. case, 300 articles were screened, retrieved from searches in PubMed/Medline, Scopus, Google Scholar, PsycInfo CINAHL, though only 12 met our eligibility criteria: eight studies preclinical models four humans. Among studies, three suggested that may influence long-term gestational or adolescent exposure CBD; two found no impact on CBD modulation addiction-relevant Δ⁹-tetrahydrocannabinol (THC); antidepressant-like males only; one greater plasma liver concentrations females compared males. human difference patient samples, healthy males, evidence differences responses trauma recall patients post-traumatic stress disorder (PTSD). No identified role effects. We discuss implications current limitations existing literature.
Language: Английский
Citations
21